Discover why Merck presents a compelling long-term investment opportunity with its discounted valuation, robust pipeline, and ...

Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year.

Merck and Eisai report mixed results from LEAP-015 trial of Keytruda and Lenvima in HER2-negative gastroesophageal cancer treatment.

We recently compiled a list of the 15 Stocks to Invest in with Steady Dividends. In this article, we are going to take a look ...

Merck & Co Inc (MRK) stock saw a decline, ending the day at $96.24 which represents a decrease of $-1.68 or -1.72% from the prior close of $97.92. The stock opened at $98.08 and touched a low of ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

Merck (MRK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Truist has recently reduced Merck & Co Inc (MRK) stock to Hold rating, as announced on January 8, 2025, according to Finviz. Earlier, on December 20, 2024, BMO Capital Markets had reduced the stock ...

The technical picture worsened for Eli Lilly stock in December as it completed a pattern known as a “Death Cross”. This ...

We recently compiled a list of the 15 Best Large-Cap Value Stocks to Buy in 2025. In this article, we are going to take a ...

We recently compiled a list of the 15 Best Cheap Stocks to Buy for 2025. In this article, we are going to take a look at ...

Key Takeaways Merck faces headwinds like declining sales of the HPV vaccine, Gardasil, and diabetes drug, Januvia. Merck ...